Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spyre Therapeutics (SYRE) Tax Provisions (2021 - 2025)

Historic Tax Provisions for Spyre Therapeutics (SYRE) over the last 5 years, with Q1 2025 value amounting to -$15000.0.

  • Spyre Therapeutics' Tax Provisions fell 14687.5% to -$15000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was -$14000.0, marking a year-over-year decrease of 12800.0%. This contributed to the annual value of $51000.0 for FY2024, which is 29615.38% up from last year.
  • Latest data reveals that Spyre Therapeutics reported Tax Provisions of -$15000.0 as of Q1 2025, which was down 14687.5% from $1000.0 recorded in Q4 2024.
  • Spyre Therapeutics' Tax Provisions' 5-year high stood at $92000.0 during Q2 2021, with a 5-year trough of -$209000.0 in Q3 2022.
  • Over the past 5 years, Spyre Therapeutics' median Tax Provisions value was $9000.0 (recorded in 2022), while the average stood at -$846.15.
  • As far as peak fluctuations go, Spyre Therapeutics' Tax Provisions plummeted by 90384.62% in 2022, and later surged by 50000.0% in 2024.
  • Quarter analysis of 5 years shows Spyre Therapeutics' Tax Provisions stood at $23000.0 in 2021, then surged by 65.22% to $38000.0 in 2022, then tumbled by 92.11% to $3000.0 in 2023, then plummeted by 66.67% to $1000.0 in 2024, then plummeted by 1600.0% to -$15000.0 in 2025.
  • Its Tax Provisions stands at -$15000.0 for Q1 2025, versus $1000.0 for Q4 2024 and $18000.0 for Q3 2024.